Acurx Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023; filed August 11, 2023. Unaudited interim financial statements.
Business context
Acurx is a clinical-stage biopharmaceutical company developing antibiotics for serious bacterial infections. Its lead candidate, ibezapolstat, is being studied for C. difficile infection (CDI); the company has no approved products and has generated no revenue. It reported 31 patients enrolled in its Phase 2b trial. An independent data monitoring committee (IDMC) is expected to review interim data once 36 patients are enrolled and recommend whether the trial should stop early or continue.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $1.74 million | $0.91 million | $2.75 million | $1.73 million |
| General and administrative expense | $1.71 million | $1.71 million | $3.60 million | $3.56 million |
| Net loss | $3.45 million | $2.62 million | $6.35 million | $5.29 million |
| Basic and diluted loss per share | $0.28 | $0.26 | $0.53 | $0.52 |
| Net cash used in operations | Not stated for quarter | Not stated for quarter | $3.51 million | $3.87 million |
Operating margins are not meaningful because the company has no revenue. At June 30, cash was $9.15 million, prepaid expenses $0.09 million, current liabilities $3.02 million, and working capital approximately $6.22 million. The filing reports no debt. Cash increased by $0.03 million during the first half, as $3.54 million of financing proceeds largely offset operating cash use.
Changes versus prior comparable periods
- Q2 net loss increased $0.82 million year over year; first-half net loss increased $1.06 million.
- R&D expense increased 90% in Q2 and 59% for the first half, primarily from Phase 2b trial and consulting costs. G&A was essentially flat.
- Cash used in operations declined by approximately $0.36 million in the first half, while the company raised approximately $3.54 million net through its May 2023 offering.
- Shares outstanding rose from 11.63 million at December 31, 2022 to 13.01 million at June 30, 2023. There were 6.88 million warrants outstanding at period-end.
Outlook, risks and unusual items
- Funding and going concern: Management stated that available cash is not expected to fund anticipated requirements for at least 12 months from issuance of the financial statements. The company expects continuing losses and negative cash flows, plans to seek additional equity financing and grants, and warns funding may not be available on acceptable terms or at all. The filing says these conditions raise substantial doubt about its ability to continue as a going concern.
- Clinical outlook: Enrollment, trial progress and IDMC recommendations remain uncertain. Management said it would report available data promptly after the IDMC review; the filing gives no specific completion date or financial guidance.
- Financing and dilution: The May 2023 registered direct offering and concurrent private placement generated approximately $4.0 million gross and $3.5 million net. The financing included warrants; existing Series A and B warrant expiry dates were extended to May 2029. These securities may contribute to future dilution.
- Non-cash item: The warrant amendment increased estimated fair value by approximately $2.0 million, recorded as an increase to additional paid-in capital and as a non-cash offering cost—not as an operating expense.
- Operating concentration: One vendor represented 70% of first-half R&D expense and 88% of accounts payable and accrued expenses at June 30. The company expects significant spending with this vendor over the next 12 months.
- Other risks: Development and regulatory failure, patient-enrollment delays, reliance on third-party manufacturers and trial providers, financing needs, and possible COVID-19-related disruption. The filing reports no material litigation and says disclosure controls were effective at a reasonable assurance level.
Most important facts for investors to verify
- Whether the IDMC review occurs at 36 enrolled patients, its recommendation, and the timing and completeness of reported trial data.
- Cash burn, updated cash runway, and the availability and terms of additional financing or grant funding.
- Current patient enrollment and trial-site status, including any enrollment or supply disruptions.
- Potential dilution from outstanding warrants, options and future financing; confirm warrant terms and share counts in subsequent filings.
- The company’s ongoing reliance on its major R&D vendor and the status of any alternative manufacturing or supply arrangements.